Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 8/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 4/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.31 |
| ▸ | CCR2 | P41597 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1996771 | 0.77 | TRPV4 (0.36) | TRPV4KDRPDGFRBKCNH2 | |
| SCHEMBL1989787 | 0.75 | KCNH2 (0.38) | TRPV4KDRPDGFRBKCNH2 | |
| SCHEMBL2000199 | 0.73 | KCNH2 (0.35) | TRPV4CCR2KCNH2 | |
| SCHEMBL2233206 | 0.68 | SLC22A12 (0.34) | TRPV4 | |
| SCHEMBL2234818 | 0.67 | P2RY1 (0.38) | — | |
| SCHEMBL11920288 | 0.67 | TSHR (0.36) | DPP4 | |
| SCHEMBL1991949 | 0.66 | TSHR (0.35) | DPP4 | |
| Hydrochloric Acid SCHEMBL2234244 | 0.66 | TSHR (0.35) | DPP4 | |
| SCHEMBL31452455 | 0.64 | TLR7 (0.40) | KDRPDGFRBCCR2KCNH2 | |
| SCHEMBL31452417 | 0.64 | HTT (0.36) | KDRPDGFRBCCR2KCNH2SCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1866310-B1 | 2,3-SUBSTITUTED FUSED PYRIMIDIN-4(3H)-ONES AS VR1 ANTAGONISTS | MERCK SHARP & DOHME (GB) | 2012-07-11 | — | — | EP | disclosed |
| US-20110152242-A1 | 2,3-Substituted Fused Pyrimidin -4 (3H)-Ones as VR1 Antagonists | MERCK SHARP & DOHME LTD. (GB) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152242-A1 | 2,3-Substituted Fused Pyrimidin -4 (3H)-Ones as VR1 Antagonists | NR2C2, NR3C2, NR2E3 | TRPV4 1580/4885DPP4 4315/4885KDR 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.